CEO David DeStefano highlighted Vertex's strong start to 2025, reporting $177.1 million in revenue, a 12.9% year-over-year increase, supported by 14.4% growth in subscription revenue and 29.6% growth ...

Total revenue grew 3% year-over-year in the first quarter, driven primarily by the continued performance of TRIKAFTA, KAFTRIO and an early contribution from the U.S. launch of ALYFTREK. Revenue ...

CEO Reshma Kewalramani highlighted a strong start to 2025 with $2.77 billion in revenue for Q1, marking a 3% increase over Q1 2024. She emphasized the successful launches of ALYFTREK, JOURNAVX, and ...

Wagner reiterated Vertex's 2025 total revenue guidance of $11.85 billion to $12 billion, representing approximately 8% growth at midpoint. This outlook reflects ongoing ALYFTREK and CASGEVY launches, ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. On the bright side, early momentum for newly launched cystic fibrosis (CF) med Alyftrek and pain treatment ...

Wagner guided, "We expect full year 2026 total company revenue to be in the range of $12.95 billion to $13.1 billion, representing 8% to 9% growth versus the prior year. This outlook anticipates ...

Cystic fibrosis (CF) specialist Vertex is tracking two newer launches that speak to its efforts to expand its prowess beyond those roots. Despite mixed early results for those rollouts so far, the ...